Pramanicin Analog Induces Apoptosis in Human Colon Cancer Cells: Critical Roles for Bcl-2, Bim, and p38 MAPK Signaling

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Bodur, Cagri ^a   Kutuk, Ozgur ^b   Karsli Uzunbas, Gizem ^a   Isimjan, Tayirjan T ^c   Harrison, Paul ^c   Basaga, Huveyda ^a  

^a SABANCI UNIVERSITY   (Turkey)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIM PROTEIN; CASPASE 3; CASPASE 9; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PRAMANICIN DERIVATIVE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOCHONDRION; PROTEIN CLEAVAGE; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; EPOXY COMPOUNDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LACTAMS; MEMBRANE PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84874186927     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056369     Document Type: Article

References (69)

1. Kwan CY, Harrison PH, Kwan TK, (2003) Pramanicin, an antifungal agent, raises cytosolic Ca2+ and causes cell death in vascular endothelial cells. Vascul Pharmacol 40: 35-42.
2. Kutuk O, Pedrech A, Harrison P, Basaga H, (2005) Pramanicin induces apoptosis in Jurkat leukemia cells: a role for JNK, p38 and caspase activation. Apoptosis 10: 597-609.
3. Blank JL, Gerwins P, Elliott EM, Sather S, Johnson GL, (1996) Molecular cloning of mitogen-activated protein/ERK kinase kinases (MEKK) 2 and 3. Regulation of sequential phosphorylation pathways involving mitogen-activated protein kinase and c-Jun kinase. J Biol Chem 271: 5361-8.
4. Nunez G, Benedict MA, Hu Y, Inohara N, (1998) Caspases: the proteases of the apoptotic pathway. Oncogene 17: 3237-45.
5. Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, et al. (2006) Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8: 1348-58.
6. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, et al. (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-9.
7. Miyashita T, Reed JC, (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-9.
8. Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, et al. (2002) BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 4: 842-9.
9. Nakano K, Vousden KH, (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7: 683-94.
10. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, et al. (2000) Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053-8.
11. Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, et al. (2001) DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 20: 2225-34.
12. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, et al. (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15: 3032-40.
13. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, et al. (1998) p53-dependent and-independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 58: 1593-8.
14. Erster S, Moll UM, (2005) Stress-induced p53 runs a transcription-independent death program. Biochem Biophys Res Commun 331: 843-50.
15. Talos F, Petrenko O, Mena P, Moll UM, (2005) Mitochondrially targeted p53 has tumor suppressor activities in vivo. Cancer Res 65: 9971-81.
16. Budhram-Mahadeo V, Morris PJ, Smith MD, Midgley CA, Boxer LM, et al. (1999) p53 suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor. J Biol Chem 274: 15237-44.
17. Wu Y, Mehew JW, Heckman CA, Arcinas M, Boxer LM, (2001) Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 20: 240-51.
18. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-501.
19. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B, (2000) Role of BAX in the apoptotic response to anticancer agents. Science 290: 989-92.
20. Harrison PHM, Duspara PA, Jenkins SI, Kassam SA, Liscombe DK, et al. (2000) The biosynthesis of pramanicin in Stagonospora sp ATCC 74235: a modified acyltetramic acid. Journal of the Chemical Society-Perkin Transactions 1: 4390-4402.
21. Kwan CY, Harrison PH, Duspara PA, Daniel EE, (2001) Vasorelaxant effects of pramanicin, an anti-fungal agent: selective action on endothelial cells. Jpn J Pharmacol 85: 234-40.
22. Kwan CY, Zhang WB, Miller J, Harrison PH, Kassan S, et al. (2003) The epoxy group of pramanicin is required for the optimal endothelium-dependent relaxation of rat aorta. J Pharmacol Sci 92: 203-8.
23. Nagasaka T, Imai T, (1995) Synthesis of Chiral Pyrrolidine Derivatives from (S)-Pyroglutamic Acid.1. 7-Substituted (2r,5s)-2-Aryl-1-Aza-3-Oxabicyclo[3.3.0]Octan-8-Ones, 7-Substituted (2r,5s)-2-Aryl-1-Aza-3-Oxabicyclo[3.3.0]Oct-6-En-8-Ones and 3-Substituted (S)-5-(Hydroxymethyl)-2-Pyrrolidinones. Chemical & Pharmaceutical Bulletin 43: 1081-1088.
24. Christoffers J, Werner T, Unger S, Frey W (2003) Preparation of acyloins by cerium-catalyzed, direct hydroxylation of beta-dicarbonyl compounds with molecular oxygen. European Journal of Organic Chemistry: 425-431.
25. Rajpal A, Cho YA, Yelent B, Koza-Taylor PH, Li D, et al. (2003) Transcriptional activation of known and novel apoptotic pathways by Nur77 orphan steroid receptor. EMBO J 22: 6526-36.
26. Igata E, Inoue T, Ohtani-Fujita N, Sowa Y, Tsujimoto Y, et al. (1999) Molecular cloning and functional analysis of the murine bax gene promoter. Gene 238: 407-15.
27. Zhang T, Wang P, Ren H, Fan J, Wang G, (2009) NGFI-B nuclear orphan receptor Nurr1 interacts with p53 and suppresses its transcriptional activity. Mol Cancer Res 7: 1408-15.
28. Chintharlapalli S, Burghardt R, Papineni S, Ramaiah S, Yoon K, et al. (2005) Activation of Nur77 by selected 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes induces apoptosis through nuclear pathways. J Biol Chem 280: 24903-14.
29. Li QX, Ke N, Sundaram R, Wong-Staal F, (2006) NR4A1, 2, 3-an orphan nuclear hormone receptor family involved in cell apoptosis and carcinogenesis. Histol Histopathol 21: 533-40.
30. Grimm T, Schneider S, Naschberger E, Huber J, Guenzi E, et al. (2005) EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of BAX. Blood 105: 3263-9.
31. Bentires-Alj M, Dejardin E, Viatour P, Van Lint C, Froesch B, et al. (2001) Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. Oncogene 20: 2805-13.
32. Shou Y, Li N, Li L, Borowitz JL, Isom GE, (2002) NF-kappaB-mediated up-regulation of Bcl-X(S) and Bax contributes to cytochrome c release in cyanide-induced apoptosis. J Neurochem 81: 842-52.
33. Vogler M, Dinsdale D, Dyer MJ, Cohen GM, (2009) Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 16: 360-7.
34. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-81.
35. Galsky MD, Vogelzang NJ, (2010) Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol 21: 2135-44.
36. Wei J, Stebbins JL, Kitada S, Dash R, Placzek W, et al. (2010) BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 53: 4166-76.
37. Weecharangsan W, Yu B, Zheng Y, Liu S, Pang JX, et al. (2009) Efficient delivery of antisense oligodeoxyribonucleotide g3139 by human serum albumin-coated liposomes. Mol Pharm 6: 1848-55.
38. Moulder SL, Symmans WF, Booser DJ, Madden TL, Lipsanen C, et al. (2008) Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res 14: 7909-16.
39. Heist RS, Fain J, Chinnasami B, Khan W, Molina JR, et al. (2010) Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol 5: 1637-43.
40. Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, et al. (2010) A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol 66: 1079-85.
41. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, et al. (2010) Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11: 1149-59.
42. Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, et al. (2009) Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 16: 1030-9.
43. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH, (2011) Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs 16: 59-70.
44. Bodur C, Basaga H, (2012) Bcl-2 inhibitors: emerging drugs in cancer therapy. Curr Med Chem 19: 1804-20.
45. de las Alas MM, Aebi S, Fink D, Howell SB, Los G, (1997) Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst 89: 1537-41.
46. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, et al. (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393-403.
47. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, et al. (1998) Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 17: 384-95.
48. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A, (1999) The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 3: 287-96.
49. Lei K, Davis RJ, (2003) JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci U S A 100: 2432-7.
50. Pazyra-Murphy MF, Hans A, Courchesne SL, Karch C, Cosker KE, et al. (2009) A retrograde neuronal survival response: target-derived neurotrophins regulate MEF2D and bcl-w. J Neurosci 29: 6700-9.
51. Andrews SF, Dai X, Ryu BY, Gulick T, Ramachandran B, et al. (2012) Developmentally regulated expression of MEF2C limits the response to BCR engagement in transitional B cells. Eur J Immunol 42: 1327-36.
52. Lee SO, Abdelrahim M, Yoon K, Chintharlapalli S, Papineni S, et al. (2010) Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits pancreatic cancer cell and tumor growth. Cancer Res 70: 6824-36.
53. Li ZL, Abe H, Ueki K, Kumagai K, Araki R, et al. (2003) Identification of c-Jun as bcl-2 transcription factor in human uterine endometrium. J Histochem Cytochem 51: 1601-9.
54. Wajapeyee N, Britto R, Ravishankar HM, Somasundaram K, (2006) Apoptosis induction by activator protein 2alpha involves transcriptional repression of Bcl-2. J Biol Chem 281: 16207-19.
55. Dong L, Wang W, Wang F, Stoner M, Reed JC, et al. (1999) Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem 274: 32099-107.
56. Duan H, Heckman CA, Boxer LM, (2005) Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25: 1608-19.
57. Green DR, Mahboubi A, Nishioka W, Oja S, Echeverri F, et al. (1994) Promotion and inhibition of activation-induced apoptosis in T-cell hybridomas by oncogenes and related signals. Immunol Rev 142: 321-42.
58. Nesbit CE, Fan S, Zhang H, Prochownik EV, (1998) Distinct apoptotic responses imparted by c-myc and max. Blood 92: 1003-10.
59. Barthson J, Germano CM, Moore F, Maida A, Drucker DJ, et al. (2011) Cytokines tumor necrosis factor-alpha and interferon-gamma induce pancreatic beta-cell apoptosis through STAT1-mediated Bim protein activation. J Biol Chem 286: 39632-43.
60. Heckman CA, Mehew JW, Boxer LM, (2002) NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 21: 3898-908.
61. Yamamoto K, Ichijo H, Korsmeyer SJ, (1999) BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 19: 8469-78.
62. Bodur C, Kutuk O, Tezil T, Basaga H, (2012) Inactivation of Bcl-2 through IkappaB kinase (IKK)-dependent phosphorylation mediates apoptosis upon exposure to 4-hydroxynonenal (HNE). J Cell Physiol 227: 3556-65.
63. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, et al. (2010) Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463: 103-7.
64. Lim EJ, Lee SH, Lee JG, Kim JR, Yun SS, et al. (2007) Toll-like receptor 9 dependent activation of MAPK and NF-kB is required for the CpG ODN-induced matrix metalloproteinase-9 expression. Exp Mol Med 39: 239-45.
65. Hara S, Arai M, Tomaru K, Doi H, Koitabashi N, et al. (2008) Prostaglandin F2alpha inhibits SERCA2 gene transcription through an induction of Egr-1 in cultured neonatal rat cardiac myocytes. Int Heart J 49: 329-42.
66. Vitale I, Senovilla L, Galluzzi L, Criollo A, Vivet S, et al. (2008) Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells. Cell Cycle 7: 1956-61.
67. Tuli R, Seghatoleslami MR, Tuli S, Howard MS, Danielson KG, et al. (2002) p38 MAP kinase regulation of AP-2 binding in TGF-beta1-stimulated chondrogenesis of human trabecular bone-derived cells. Ann N Y Acad Sci 961: 172-7.
68. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, et al. (1999) Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2,-3,-6,-7,-8, and-10 in a caspase-9-dependent manner. J Cell Biol 144: 281-92.
69. Ryan KM, Phillips AC, Vousden KH, (2001) Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13: 332-7.